Navigation Links
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Date:5/3/2012

ble bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014  Dr. Navneet Sharda M.D . ... recently announced their continued investment in cutting edge cancer treatments ... at the Center and a national reputation as leaders in ... speaking with multiple cancer survivors who have undergone cancer treatment ... both his warm, friendly manner and his belief in the ...
(Date:9/15/2014)... 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... stringent listing criteria for the NASDAQ Global Select Market ... exchange from the NYSE MKT. The company will continue ... NASDAQ Global Select Market, a segment of ... standards of any exchange in the world, requiring that ...
(Date:9/15/2014)... 2014  The Female Health Company (NASDAQ-CM: FHCO) today ... Company,s management team as Executive Vice President of Global ... that Michael Pope will retire from his ... September 15, 2014.  Following his retirement, Mr. Pope will ... Prior to joining The Female Health Company ...
Breaking Medicine Technology:Cancer Care Center Emphasizing Innovative Oncology Treatments 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 3The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 2The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 3
... May 9, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... abstracts at the 2011 Digestive Disease Week (DDW) conference ... of DIFICID™ (fidaxomicin), an investigational product for the treatment ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The first analysis ...
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2
(Date:9/15/2014)... September 15, 2014 The Best ... World Report consists of seven hospitals using OnBase as ... Hospital and Cleveland Clinic were ranked at the top ... respectively. The rankings cover nearly 5,000 medical centers across ... 17 hospitals that scored highest in at least six ...
(Date:9/15/2014)... 2014 (HealthDay News) -- U.S. heart experts recommend doctors ... when evaluating young people for underlying heart disease that ... Heart Association and the American College of Cardiology said ... and family medical history along with a physical examination ... (existing from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... estimated 8% of Americans will suffer from post traumatic ... Brought on by an overwhelming or stressful event or ... physiology of the brain. Understanding how threat is processed ... is essential to developing effective interventions. , New ... of Texas at Dallas published online today in ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 This year, ... its founding in 2007. To mark the special occasion, ... for supporting the village and helping it to get ... safe, secure and fun community for seniors. Members of ... community and live in their own homes. They are ...
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... responsible for sending thousands of young children to the hospital ... year between 2007 and 2011, about 9,500 U.S. children younger ... family members, medication, according to the U.S. Centers for Disease ... just 1 or 2 years old," said Dr. Daniel Budnitz, ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:EEG study findings reveal how fear is processed in the brain 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... Axel Ullrich, Ph.D., is the recipient of the ... his pioneering work in the translation of genomics-based discoveries ... Director of Molecular Biology at the Max Planck Institute ... expert in gene technology and one of the most ...
... of activity helped men, women regardless of family history ... level of aerobic fitness can significantly reduce stroke risk ... study. , The study, expected to be presented Thursday ... New Orleans, showed 30 minutes or more of brisk ...
... connection, experts say , , THURSDAY, Feb. 21 (HealthDay News) ... anywhere else for that matter, may raise your risk ... , "These authors report a potentially important association between ... said Dr. Steven V. Pacia, director of neurology at ...
... similarities, differences in DNA, studies find , , THURSDAY, ... such examination of human genetic diversity yet conducted, an ... to track differences and similarities between people around the ... Science , a team led by Richard Myers, ...
... drugs raises risk of adverse side effects ... take more than one nonsteroidal anti-inflammatory drug (NSAID) may ... suggests. , NSAIDs, which are available in both prescription ... arthritis. , These drugs are widely available, and patients ...
... release is available in Spanish . , ... field of health. However, they are vitally important for patients ... carried out at the Department of Social Anthropology ... lecturer Rafael Briones Gmez, shows that Spanish hospitals are not ...
Cached Medicine News:Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 2Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 3Health News:Moderate Aerobic Fitness Levels May Cut Stroke Risk 2Health News:Daytime Dozing Might Raise Stroke Risk 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 3Health News:Global Analysis of Human DNA Tracks Migration, Identity 4Health News:Taking Multiple Pain Relievers May Cause Complications 2Health News:Patients' relatives are ignored by the health system and suffer emotional stress 2
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
Medicine Products: